Axis Securities Initiates Coverage on Marksans Pharma

What just happened

Axis Securities has initiated coverage on Marksans Pharma, forecasting significant revenue growth driven by international expansion and manufacturing scale-up.

Reader Takeaway: Marksans Pharma eyes Rs 6,000 Cr revenue by FY30; faces risks from raw material price volatility.

Why this matters

The brokerage firm highlights Marksans Pharma’s strategic moves into regulated European markets through the acquisitions of QliniQ B.V. and ABCnow GmbH. The company aims to generate Rs 1,000 Cr in European revenues within the next 3–5 years. Furthermore, the ramp-up of the Teva Goa manufacturing site is expected to be a primary volume driver, supported by a global formulation capacity of 26 billion units per annum.

The backstory

Marksans Pharma continues to leverage its R&D capabilities, currently managing a pipeline of over 200 products in development and holding more than 350 approved ANDAs/MAs. The company remains in a strong liquidity position, with a net cash balance exceeding Rs 1,000 Cr, enabling it to fund future growth organically and through potential inorganic acquisitions.

What changes now

Management has set a long-term goal to reach Rs 6,000 Cr in revenue by FY30. The firm is targeting to maintain its EBITDA margins in the 20–22% range. Forecasts suggest a steady trajectory, with projected PAT growing from Rs 410 Cr in FY25 to an estimated Rs 732 Cr by FY28.

Risks to watch

Growth remains subject to operational risks, specifically potential delays in new product approvals and the speed of the capacity ramp-up. Additionally, fluctuations in raw material and solvent prices could impact margin stability.

What to track next

Investors should monitor the successful integration of recent European acquisitions, the utilization rates at the Goa facility, and the firm’s ability to adhere to its EBITDA margin guidance in coming quarters.